Comparative Pharmacology
Head-to-head clinical analysis: ORETON METHYL versus TREST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORETON METHYL versus TREST.
ORETON METHYL vs TREST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyltestosterone is a synthetic androgen that binds to androgen receptors, activating transcription of androgen-responsive genes, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development.
Mirtazapine is a tetracyclic antidepressant that acts as a potent antagonist of central α2-adrenergic autoreceptors and heteroreceptors, leading to increased norepinephrine and serotonin neurotransmission. It also antagonizes 5-HT2 and 5-HT3 receptors, with no significant effect on serotonin reuptake.
10-50 mg orally or buccally 1-3 times daily; or 25-100 mg IM every 2-4 weeks.
10-15 mg orally every 6 hours as needed for agitation in dementia; maximum 60 mg/day.
None Documented
None Documented
Terminal half-life approximately 2.7–3.8 hours; brief due to rapid hepatic metabolism.
Terminal elimination half-life: 4–6 hours (clinically, dosing every 6–8 hours maintains therapeutic levels).
Primarily renal as conjugated metabolites; ~90% urinary, ~6% fecal within 4 days.
Renal: 80% unchanged; biliary/fecal: 10% as metabolites; 10% other.
Category C
Category C
Androgen
Androgen